Madrigal Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MDGL research report →
Companywww.madrigalpharma.com
Madrigal Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis.
- CEO
- William J. Sibold
- IPO
- 2007
- Employees
- 528
- HQ
- West Conshohocken, PA, US
Price Chart
Valuation
- Market Cap
- $11.74B
- P/E
- -47.77
- P/S
- 10.37
- P/B
- 27.20
- EV/EBITDA
- -41.22
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 93.07%
- Op Margin
- -27.68%
- Net Margin
- -27.32%
- ROE
- -50.15%
- ROIC
- -35.20%
Growth & Income
- Revenue
- $958.40M · 432.05%
- Net Income
- $-288,284,000 · 38.12%
- EPS
- $-12.85 · 41.32%
- Op Income
- $-300,097,000
- FCF YoY
- 58.42%
Performance & Tape
- 52W High
- $615.00
- 52W Low
- $265.00
- 50D MA
- $502.51
- 200D MA
- $481.73
- Beta
- -1.04
- Avg Volume
- 329.15K
Get TickerSpark's AI analysis on MDGL
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 18, 26 | Soergel David | sell | 844 |
| Mar 4, 26 | Dier Mardi | other | 5,215 |
| Mar 6, 26 | Dier Mardi | sell | 646 |
| Mar 6, 26 | Dier Mardi | sell | 40 |
| Mar 6, 26 | Dier Mardi | sell | 420 |
| Mar 6, 26 | Dier Mardi | sell | 80 |
| Mar 6, 26 | Dier Mardi | sell | 160 |
| Mar 6, 26 | Dier Mardi | sell | 40 |
| Mar 6, 26 | Dier Mardi | sell | 120 |
| Mar 6, 26 | Dier Mardi | sell | 116 |
Our MDGL Coverage
We haven't published any research on MDGL yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate MDGL Report →